{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:15Z","timestamp":1792181595602,"version":"4.4.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T00:00:00Z","timestamp":1609286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The survival benefit of combination antifungal therapy for invasive mucormycosis (IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT) is not well defined.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter, retrospective study included HM and HCT recipients with proven or probable IM between January 1, 2007 and December 31, 2017 from 10 transplant centers across North America.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Sixty-four patients with proven (n\u2005=\u200547) or probable (n\u2005=\u200517) IM defined by 2008 European Organization for Research and Treatment of Cancer\/Mycoses Study Group (EORTC\/MSG) consensus definitions were included. Thirty-nine (61%) were HCT recipients (95% allogeneic). Sites of infection included rhino-orbital-cerebral (33), pulmonary (30%), disseminated (19%), gastrointestinal (3%), and cutaneous (3%). Surgical debridement was performed in 66%. Initial antifungal treatment consisted of the following: lipid formulation of amphotericin B (AmB) alone (44%), AmB\u2005+\u2005posaconazole (25%), AmB\u2005+\u2005echinocandin (13%), AmB\u2005+\u2005isavuconazole (8%), posaconazole alone (5%), and isavuconazole alone (3%). All-cause mortality at 30 days and 1 year were 38% and 66%, respectively. Initial treatment with AmB plus posaconazole or isavuconazole (n\u2005=\u200528) was associated with a trend toward lower treatment failure compared with AmB (n\u2005=\u200521) (42% vs 64%, P\u2005=\u2005.136).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Long-term survival with IM among HM and HCT populations remains poor. However, initial use of AmB\u2005+\u2005azole in conjunction with surgery may result in less treatment failure. More evidence from prospective controlled studies is needed to confirm this observation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofaa646","type":"journal-article","created":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T03:00:04Z","timestamp":1609297204000},"source":"Crossref","is-referenced-by-count":40,"title":["Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents"],"prefix":"10.1093","volume":"8","author":[{"given":"Matthew A","family":"Miller","sequence":"first","affiliation":[{"name":"Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle C","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan A","family":"Gutman","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Colorado Denver, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sias","family":"Scherger","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado Denver, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M","family":"Lum","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Respiratory Institute and Transplant Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif B","family":"Mossad","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Respiratory Institute and Transplant Center, Cleveland Clinic Foundation, Cleveland, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Burgess","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Arkansas, Fayetteville, Arkansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P","family":"Cheng","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, McGill University Health Centre, Montreal, Canada"},{"name":"Division of Medical Microbiology, McGill University Health Centre, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally T","family":"Chuang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Rochester, Rochester, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha E","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante P","family":"Melendez","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimpy P","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Nebraska, Lincoln, Nebraska, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M Rizwan","family":"Sohail","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadia","family":"Syed","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall C","family":"Walker","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M","family":"Poeschla","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado Denver, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1096-1043","authenticated-orcid":false,"given":"Maheen Z","family":"Abidi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Colorado Denver, Denver, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"2021020514574318600_CIT0001","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021020514574318600_CIT0002","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.3201\/eid1710.110087","article-title":"Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006","volume":"17","author":"Park","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"2021020514574318600_CIT0003","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"2021020514574318600_CIT0004","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021020514574318600_CIT0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1469-0691.2009.02988.x","article-title":"Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?","volume":"15","author":"Pongas","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"2021020514574318600_CIT0006","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2021020514574318600_CIT0007","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/S0399-077X(08)73003-8","article-title":"[AMBIZYGO: phase II study of high dose liposomal amphotericin B (AmBisome) [10 mg\/kg\/j] efficacy against zygomycosis]","volume":"38","author":"Lanternier","year":"2008","journal-title":"Med Mal Infect"},{"key":"2021020514574318600_CIT0008","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12941-019-0311-3","article-title":"Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center","volume":"18","author":"Van Matre","year":"2019","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2021020514574318600_CIT0009","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/jac\/dkv380","article-title":"Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease","volume":"71","author":"Cornely","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2021020514574318600_CIT0010","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.1128\/AAC.03050-14","article-title":"Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia","volume":"58","author":"Duarte","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020514574318600_CIT0011","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.02686-13","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020514574318600_CIT0012","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020514574318600_CIT0013","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020514574318600_CIT0014","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021020514574318600_CIT0015","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/AAC.01124-08","article-title":"Posaconazole mono- or combination therapy for treatment of murine zygomycosis","volume":"53","author":"Ibrahim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021020514574318600_CIT0016","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021020514574318600_CIT0017","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"2021020514574318600_CIT0018","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/myc.12222","article-title":"Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies","volume":"57","author":"Abidi","year":"2014","journal-title":"Mycoses"},{"key":"2021020514574318600_CIT0019","doi-asserted-by":"crossref","first-page":"811.e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"2021020514574318600_CIT0020","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaa646\/35254932\/ofaa646.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/2\/ofaa646\/36199817\/ofaa646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/8\/2\/ofaa646\/36199817\/ofaa646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T13:58:40Z","timestamp":1612792720000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaa646\/6055169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaa646","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,12,30]]},"article-number":"ofaa646"}}